ALS (ASX: ALQ) – ALS 2025 Half Yearly Report

ALS Limited reported underlying net profit after tax of $214.6 million for the half year ended 30 September 2026, up 23.6 percent compared to the prior corresponding period. The stronger profit growth relative to reported revenue growth of just 3.4 percent reflects the company’s operational leverage, as underlying earnings before interest and tax margins expanded 250 basis points to 19.4 percent. The revenue result masks stronger underlying performance, with organic revenue growth of 10.2 percent offset by a 6.2 percent headwind from foreign exchange as the Australian dollar strengthened during the first half. This combination reveals a business that is genuinely growing faster than headline figures suggest while demonstrating improved operational discipline.

The Commodities division delivered particularly robust results, with underlying earnings before interest and tax climbing 36.4 percent to $233.1 million. The segment achieved organic revenue growth of 24.5 percent, driven predominantly by the Minerals business where sample volumes increased across major, mid-tier and junior exploration companies. The operating margin expanded 371 basis points to 31.6 percent, reflecting the benefits of pricing discipline, operational efficiencies and revenue mix. Management attributed the strong performance to favourable market conditions and increased capital deployment into mineral exploration, positioning the company to benefit from electrification trends driving base metal demand for clean energy transition. The company notes that growth will moderate in the second half as it cycles tougher year-on-year comparisons.

The Life Sciences division reported a 12.6 percent decline in underlying earnings before interest and tax to $134.0 million, with management identifying specific challenges within the USA Environmental business and at the Nuvisan pharmaceutical contract manufacturing unit. The company has implemented new leadership and operational changes in the USA division, with cost and commercial initiatives underway at Nuvisan. Food testing grew organically by 6.8 percent while Environmental grew 2.1 percent, but Pharmaceutical contracted 4.1 percent as delayed order conversion affected results. Management expects Life Sciences to return to mid-single digit organic growth in the second half as these initiatives take effect.

The company declared an interim dividend of 23.3 cents per share, partially franked at 35 percent, representing a 20.1 percent increase on the prior year interim and reflecting confidence in operational performance. With a leverage ratio of 1.5 times and 78 percent of drawn debt fixed at a weighted average rate of 3.7 percent, the balance sheet remains strong. Available liquidity exceeds $430 million, supporting both the acquisition of an additional 18 percent stake in Australian Laboratory Services Arabia Co. Limited in July 2026, which generated a $97.2 million fair value gain on remeasurement of the previously held interest, and the organic investment program focused on building Minerals capacity and Environmental testing capability.

A rules-based approach to leveraged ETFs

See how our quantitative strategy works and who it suits.

Explore the strategy

Become an authorised representative

Advise your clients under an established AFSL without building your own. Choose AR or CAR.

Become an AR or CAR

Performance in Life Sciences will be critical to watch, particularly whether the turnaround plan executes effectively with second-half results validating management’s recovery timeline. The Commodities division’s ability to sustain strong growth rates, particularly in Geochemistry, depends on the breadth and duration of the global exploration cycle. This announcement is price sensitive and has been flagged as material by the ASX.

View the full ASX announcement (PDF)

About ALS Limited (ASX: ALQ)

ALS Limited is a global leader in laboratory testing, inspection, certification, and verification services, operating from approximately 350 sites across 65 countries. The company operates two main divisions: Commodities, which provides assaying and metallurgical services for the mining sector, and Life Sciences, which offers analytical testing for environmental, food, pharmaceutical, and consumer products markets. Headquartered in Brisbane, Australia, ALS serves major clients across Africa, Asia Pacific, Europe, the Middle East, North Africa, and the United States.

Learn to trade with a plan

Our free 5-day course covers entries, exits and risk management.

Become an authorised representative

Advise your clients under an established AFSL without building your own. Choose AR or CAR.

Become an AR or CAR

This is general advice only. MF & Co Asset Management has not considered your personal financial needs, objectives or current situation. This information is not an offer, solicitation, or a recommendation for any financial product unless expressly stated. You should seek professional investment advice before making any investment decision.

You May Also Like…

« Older Entries

Unlock every article for free

Become an authorised representative

Advise your clients under an established AFSL without building your own. Choose AR or CAR.

Become an AR or CAR

MF & Co. Asset Management

MF & Co. Asset Management is a boutique investment firm offering Equity Capital Markets and derivative general advice & trade execution services.

We are specialists in advising and trading in Australian and US Equities, Index & Equity Options and Options on Futures.